secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0000950170-23-043561
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics appoints EisnerAmper as new auditor after MHM resignation
-----------------------------------------------------------------------------

- EisnerAmper LLP engaged as independent auditor for FY 2023 and Q3 2023 review, effective Aug 18, 2023.
- Audit Committee and Board unanimously approved the engagement; no prior consultations with EisnerAmper occurred.
- MHM resigned as auditor on Aug 21, 2023, as previously reported on July 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023043561/0000950170-23-043561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023043561/sabs-20230818.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-043561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer